R
Ruey Kuen Hsieh
Researcher at Mackay Memorial Hospital
Publications - 4
Citations - 745
Ruey Kuen Hsieh is an academic researcher from Mackay Memorial Hospital. The author has contributed to research in topics: Lapatinib & Siltuximab. The author has an hindex of 4, co-authored 4 publications receiving 635 citations. Previous affiliations of Ruey Kuen Hsieh include National Taiwan University.
Papers
More filters
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja,Andrew P. Holmes,Martine Piccart-Gebhart,Eileen Holmes,Serena Di Cosimo,Ramona F. Swaby,Michael Untch,Christian Jackisch,István Láng,Ian E. Smith,Frances M. Boyle,Binghe Xu,Carlos H. Barrios,Edith A. Perez,Hatem A. Azim,Sung Bae Kim,Sherko Kuemmel,Chiun-Sheng Huang,Peter Vuylsteke,Ruey Kuen Hsieh,Vera Gorbunova,Alexandru Eniu,Lydia Dreosti,Natalia Tavartkiladze,Richard D. Gelber,Holger Eidtmann,José Baselga +26 more
TL;DR: The NeoALTTO trial showed that 3-year event-free survival was significantly improved for women who achieved pathological complete response compared with those who did not, and the association between pathological complete responded and overall survival was assessed.
Journal ArticleDOI
Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial
Frits van Rhee,Raymond S.M. Wong,Nikhil C. Munshi,Jean-François Rossi,Xiaoyan Ke,Alexander Fosså,David Simpson,Marcelo Capra,Ting Liu,Ruey Kuen Hsieh,Yeow Tee Goh,Jun Zhu,Seok-Goo Cho,Hanyun Ren,James Cavet,Rajesh Bandekar,Margaret Rothman,Thomas A. Puchalski,Manjula Reddy,Helgi van de Velde,Jessica Vermeulen,Corey Casper +21 more
TL;DR: Siltuximab plus best supportive care was superior tobest supportive care alone for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged exposure.
Journal ArticleDOI
Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial
Hatem A. Azim,Dominique Agbor-Tarh,Ian Bradbury,Phuong Dinh,José Baselga,Serena Di Cosimo,James G. Greger,Ian E. Smith,Christian Jackisch,Sung-Bae Kim,Bahriye Aktas,Chiun-Sheng Huang,Peter Vuylsteke,Ruey Kuen Hsieh,Lydia Dreosti,Holger Eidtmann,Martine Piccart,Evandro de Azambuja +17 more
TL;DR: The results indicate that the frequency and clinical relevance of lapatinib-related rash is largely dependent on patient age.
Journal ArticleDOI
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease
Raymond S.M. Wong,Corey Casper,Nikhil C. Munshi,Xiaoyan Ke,Alexander Fosså,David Simpson,Marcelo Capra,Ting Liu,Ruey Kuen Hsieh,Yeow Tee Goh,Jun Zhu,Seok-Goo Cho,Hanyun Ren,James Cavet,Rajesh Bandekar,Margaret Rothman,Thomas A. Puchalski,Shalini Chaturvedi,Helgi van de Velde,Jessica Vermeulen,Frits van Rhee +20 more
TL;DR: The efficacy and safety of siltuximab in patients with symptomatic, measurable, HIV- and HHV-8-negative MCD in a phase 2, randomized, double-blind, controlled, multicenter study and the safety profile as defined by frequencies of treatment-emergent AEs was similar between siltUXimab and placebo.